This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Peg-AXOKINE

Regeneron Pharmaceuticals, Inc.

Drug Names(s): Pegylated AXOKINE

Description: Regeneron developed this chemically modified version of AXOKINE as a potentially more potent and longer-lasting molecule. AXOKINE is currently being evaluated in a large Phase III program for overweight and obese patients.

Partners: Nektar Therapeutics


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug